Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

NEW YORK (Reuters) - About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to a survey from consulting firm Mercer released on ...